🇺🇸 FDA
Patent

US 11066417

Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators

granted A61KA61K31/404A61K31/439

Quick answer

US patent 11066417 (Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators) held by Vertex Pharmaceuticals Incorporated expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Jul 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
47
CPC classes
A61K, A61K31/404, A61K31/439, A61K31/47, A61P